10/20/2023 0 Comments Generica crush crush 18+ versionSide effects, for example, may vary, so potentially labeling the biosimilars with individual suffixes may aid in the reporting of adverse events. This is an important decision given the fact that there are slight differences between biosimilars and the biologicals from which these drugs derive. Guidance for biosimilars labeling will include FDA’s decision on generic names for specific biosimilar products. Related: Adoption of fast-growing biosimilars segment essential ![]() ![]() ![]() It will also release a document on biosimilars product labeling in the same time period. FDA’s Center for Drug Evaluation and Research (CDER) will release a document designed to provide manufacturers with guidance on the evaluation of abuse-deterrent properties of generic opioids by the end of 2015.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |